Assessment of the anatomical position of point B and the relationship between point B dose and the dose delivered to pelvic lymph nodes in CT-based high-dose-rate brachytherapy for uterine cervical cancer

Hideaki Matsukawa, Tomonari Sasaki, Ryota Hirayama, Taka Aki Hirose, Jun Ichi Fukunaga

Research output: Contribution to journalArticle

Abstract

Purpose: To examine the anatomical position of point B and the relationship between the dose at point B and the dose delivered to the pelvic lymph nodes in computed tomography (CT)-based brachytherapy for cervical cancer. Material and methods: Forty-nine cervical cancer patients were treated at Kyushu University Hospital. For all cases, planning CT images obtained after the applicator insertion were imported to an Oncentra Brachy (Elekta AB, Stockholm, Sweden), and points A (dose prescription, 6 Gy) and points B were set according to the Manchester method. The pelvic lymph node regions (external iliac, internal iliac, and obturator) were contoured, and the anatomic positions of 98 points B in 49 patients were examined. Dose volume histogram (DVH) parameters (D100, D90, D50, D2cc, D1cc, and D0.1cc) were calculated for each lymph node region and compared with the point B dose. Results: The mean bilateral dose to point B was 1.70 ±0.18 Gy, and 26 (27%) of 98 points B were not located in any pelvic lymph node regions. The DVH analysis indicated a low degree of correlation overall, and all values were significantly different from point B doses (p < 0.05), except for D0.1cc of the external iliac node (p = 0.0594) and D1cc of the internal iliac node (p = 0.0711). Conclusions: We investigated the anatomical location of point B in patients with cervical cancer who underwent brachytherapy, and the DVH analysis revealed that the point B dose was a poor surrogate for the dose delivered to the pelvic lymph nodes.

Original languageEnglish
Pages (from-to)137-145
Number of pages9
JournalJournal of Contemporary Brachytherapy
Volume11
Issue number2
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Brachytherapy
Uterine Cervical Neoplasms
Lymph Nodes
Tomography
Sweden
Prescriptions

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Assessment of the anatomical position of point B and the relationship between point B dose and the dose delivered to pelvic lymph nodes in CT-based high-dose-rate brachytherapy for uterine cervical cancer. / Matsukawa, Hideaki; Sasaki, Tomonari; Hirayama, Ryota; Hirose, Taka Aki; Fukunaga, Jun Ichi.

In: Journal of Contemporary Brachytherapy, Vol. 11, No. 2, 01.01.2019, p. 137-145.

Research output: Contribution to journalArticle

@article{aaea318928484c509d0f6ab1e87a4b7e,
title = "Assessment of the anatomical position of point B and the relationship between point B dose and the dose delivered to pelvic lymph nodes in CT-based high-dose-rate brachytherapy for uterine cervical cancer",
abstract = "Purpose: To examine the anatomical position of point B and the relationship between the dose at point B and the dose delivered to the pelvic lymph nodes in computed tomography (CT)-based brachytherapy for cervical cancer. Material and methods: Forty-nine cervical cancer patients were treated at Kyushu University Hospital. For all cases, planning CT images obtained after the applicator insertion were imported to an Oncentra Brachy (Elekta AB, Stockholm, Sweden), and points A (dose prescription, 6 Gy) and points B were set according to the Manchester method. The pelvic lymph node regions (external iliac, internal iliac, and obturator) were contoured, and the anatomic positions of 98 points B in 49 patients were examined. Dose volume histogram (DVH) parameters (D100, D90, D50, D2cc, D1cc, and D0.1cc) were calculated for each lymph node region and compared with the point B dose. Results: The mean bilateral dose to point B was 1.70 ±0.18 Gy, and 26 (27{\%}) of 98 points B were not located in any pelvic lymph node regions. The DVH analysis indicated a low degree of correlation overall, and all values were significantly different from point B doses (p < 0.05), except for D0.1cc of the external iliac node (p = 0.0594) and D1cc of the internal iliac node (p = 0.0711). Conclusions: We investigated the anatomical location of point B in patients with cervical cancer who underwent brachytherapy, and the DVH analysis revealed that the point B dose was a poor surrogate for the dose delivered to the pelvic lymph nodes.",
author = "Hideaki Matsukawa and Tomonari Sasaki and Ryota Hirayama and Hirose, {Taka Aki} and Fukunaga, {Jun Ichi}",
year = "2019",
month = "1",
day = "1",
doi = "10.5114/jcb.2019.84419",
language = "English",
volume = "11",
pages = "137--145",
journal = "Journal of Contemporary Brachytherapy",
issn = "1689-832X",
publisher = "Termedia Publishing House Ltd.",
number = "2",

}

TY - JOUR

T1 - Assessment of the anatomical position of point B and the relationship between point B dose and the dose delivered to pelvic lymph nodes in CT-based high-dose-rate brachytherapy for uterine cervical cancer

AU - Matsukawa, Hideaki

AU - Sasaki, Tomonari

AU - Hirayama, Ryota

AU - Hirose, Taka Aki

AU - Fukunaga, Jun Ichi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: To examine the anatomical position of point B and the relationship between the dose at point B and the dose delivered to the pelvic lymph nodes in computed tomography (CT)-based brachytherapy for cervical cancer. Material and methods: Forty-nine cervical cancer patients were treated at Kyushu University Hospital. For all cases, planning CT images obtained after the applicator insertion were imported to an Oncentra Brachy (Elekta AB, Stockholm, Sweden), and points A (dose prescription, 6 Gy) and points B were set according to the Manchester method. The pelvic lymph node regions (external iliac, internal iliac, and obturator) were contoured, and the anatomic positions of 98 points B in 49 patients were examined. Dose volume histogram (DVH) parameters (D100, D90, D50, D2cc, D1cc, and D0.1cc) were calculated for each lymph node region and compared with the point B dose. Results: The mean bilateral dose to point B was 1.70 ±0.18 Gy, and 26 (27%) of 98 points B were not located in any pelvic lymph node regions. The DVH analysis indicated a low degree of correlation overall, and all values were significantly different from point B doses (p < 0.05), except for D0.1cc of the external iliac node (p = 0.0594) and D1cc of the internal iliac node (p = 0.0711). Conclusions: We investigated the anatomical location of point B in patients with cervical cancer who underwent brachytherapy, and the DVH analysis revealed that the point B dose was a poor surrogate for the dose delivered to the pelvic lymph nodes.

AB - Purpose: To examine the anatomical position of point B and the relationship between the dose at point B and the dose delivered to the pelvic lymph nodes in computed tomography (CT)-based brachytherapy for cervical cancer. Material and methods: Forty-nine cervical cancer patients were treated at Kyushu University Hospital. For all cases, planning CT images obtained after the applicator insertion were imported to an Oncentra Brachy (Elekta AB, Stockholm, Sweden), and points A (dose prescription, 6 Gy) and points B were set according to the Manchester method. The pelvic lymph node regions (external iliac, internal iliac, and obturator) were contoured, and the anatomic positions of 98 points B in 49 patients were examined. Dose volume histogram (DVH) parameters (D100, D90, D50, D2cc, D1cc, and D0.1cc) were calculated for each lymph node region and compared with the point B dose. Results: The mean bilateral dose to point B was 1.70 ±0.18 Gy, and 26 (27%) of 98 points B were not located in any pelvic lymph node regions. The DVH analysis indicated a low degree of correlation overall, and all values were significantly different from point B doses (p < 0.05), except for D0.1cc of the external iliac node (p = 0.0594) and D1cc of the internal iliac node (p = 0.0711). Conclusions: We investigated the anatomical location of point B in patients with cervical cancer who underwent brachytherapy, and the DVH analysis revealed that the point B dose was a poor surrogate for the dose delivered to the pelvic lymph nodes.

UR - http://www.scopus.com/inward/record.url?scp=85071272406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071272406&partnerID=8YFLogxK

U2 - 10.5114/jcb.2019.84419

DO - 10.5114/jcb.2019.84419

M3 - Article

AN - SCOPUS:85071272406

VL - 11

SP - 137

EP - 145

JO - Journal of Contemporary Brachytherapy

JF - Journal of Contemporary Brachytherapy

SN - 1689-832X

IS - 2

ER -